Calithera Biosciences Inc. (CALA) 7.40 $CALA Re
Post# of 273327
Posted On: 08/01/2015 2:51:23 AM
Calithera Biosciences Inc. (CALA) 7.40 $CALA
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 4.04 (+0.07), AMBX: (), CLDX: 23.55 (+0.03), AMGN: 176.59 (+4.90), LLY: 84.51 (-0.03), AMPE: 2.68 (+0.08), GSK: 43.44 (-0.15), BMY: 65.64 (+1.18), CLBS: 1.65 (-0.08), ARGS: 6.10 (-0.08), NK: 30.60 (-0.90), CALA: 7.40 (-0.10), EXEL: 5.73 (+0.19), XLRN: 28.64 (+0.54)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 26.22 (+0.43), ARQL: 1.71 (+0.08), LLY: 84.51 (-0.03), GSK: 43.44 (-0.15), EGRX: 96.62 (-0.16), BMY: 65.64 (+1.18), MRK: 58.96 (+0.44), AVEO: 1.41 (+0.03), CALA: 7.40 (-0.10), JUNO: 48.92 (+1.15), FPRX: 23.52 (+0.44), CXRX: 79.40 (-0.05)
5 Health Care Stocks Ready for Breakouts
at The Street - Fri Jul 17, 8:40AM CDT
These stocks look ready to break out and trade higher from current levels.
GNMK: 8.50 (+0.02), HWAY: 12.66 (+0.18), CALA: 7.40 (-0.10), AKBA: 9.40 (unch), OTIC: 25.77 (+0.26)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Thu Jul 16, 1:01PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PTX: 4.98 (+0.17), CALA: 7.40 (-0.10), MNKD: 4.29 (-0.17), SYMX: 1.25 (+0.02)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT
FIT: 47.60 (+2.41), PIRS: 3.20 (+0.14), KITE: 72.77 (+1.47), SRPT: 31.92 (+0.16), WSH: 46.49 (-0.13), CALA: 7.40 (-0.10), CLLS: 35.74 (+1.27), LBIO: 8.56 (+0.40), JUNO: 48.92 (+1.15), PNR: 60.81 (+0.07), APOL: 12.81 (-0.48), DSKX: 3.50 (+0.12)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jun 29, 4:35PM CDT
UAE: 20.45 (+0.02), TVIX: 5.70 (-0.02), BLCM: 20.35 (+0.35), EBIO: 2.77 (+0.02), XNET: 9.25 (+0.09), CALA: 7.40 (-0.10), BBEP: 3.03 (-0.26), AKBA: 9.40 (unch), LBIO: 8.56 (+0.40)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jun 19, 11:46AM CDT
FBIO: 3.37 (-0.09), ADXS: 16.66 (+0.84), ANY: 4.95 (-0.08), BITI: 17.93 (+0.16), JMEI: 18.71 (+1.42), ZAZA: 0.58 (-0.02), NSLP: 1.43 (-0.01), CORI: 14.66 (+0.66), TOPS: 1.17 (-0.03), UEC: 1.34 (-0.01), IPCI: 3.37 (-0.08), PLM: 0.94 (+0.01), CALA: 7.40 (-0.10), SPP: 1.65 (-0.03), ENRJ: 1.21 (unch), CARV: 6.05 (+0.17), PGN: 0.74 (-0.13), NNBR: 22.83 (-0.44), TCON: 13.62 (+0.45), WLDN: 10.32 (-0.02)
Calithera Biosciences to Present at the JMP Securities Life Sciences Conference 2015
GlobeNewswire - Tue Jun 16, 8:00AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the JMP Securities Life Sciences Conference 2015. Susan M. Molineaux, Ph.D., Founder, President and Chief Executive, will present on Tuesday, June 23, 2015 at 9:30 a.m. Eastern Time at The St. Regis Hotel in New York, NY. The presentation will be webcast live and available for replay for up to 30 days at www.calithera.com under the tab Investors.
CALA: 7.40 (-0.10)
Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Acute Leukemias at the 20th Congress of the European Hematology Association
GlobeNewswire - Thu Jun 11, 3:05PM CDT
Promising Clinical Activity With Early Signs of Biologic Activity, Tolerability, and Durability
CALA: 7.40 (-0.10)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 104.28 (+1.32), IDRA: 3.58 (+0.13), GILD: 117.86 (-0.04), CALA: 7.40 (-0.10), ABBV: 70.01 (-0.15), NVS: 103.75 (+0.57), CELGZ: 2.04 (+0.01), KPTI: 20.52 (+0.44)
ASCO Event Analyzer - 2015's Winners And Losers
EP Vantage - Seeking Alpha - Thu Jun 04, 1:42PM CDT
Neither Bristol-Myers Squibb (NYSE: BMY ) nor Puma Biotechnology (NYSE: PBYI ) can be scored numerically as the biggest loser coming out of ASCO, but in terms of sentiment, they were neck-and-neck for that title. Both took heavy losses after...
RXDX: 13.86 (+0.40), CLLS: 35.74 (+1.27), CALA: 7.40 (-0.10), IMGN: 18.02 (+0.12), JUNO: 48.92 (+1.15), CTIC: 1.85 (unch), BMY: 65.64 (+1.18), ONTY: 3.64 (+0.14), PBYI: 90.60 (+6.47)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qwcpw/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Conkwest, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG For more information visit http://www.researchandmarkets.com/research/7q...psed_acute
EPZM: 22.31 (-0.02), CTIC: 1.85 (unch), ABBV: 70.01 (-0.15), EXEL: 5.73 (+0.19), MGNX: 37.60 (+0.44), INCY: 104.28 (+1.32), AMGN: 176.59 (+4.90), BMY: 65.64 (+1.18), GSK: 43.44 (-0.15), ATNM: 2.26 (+0.10), AZN: 33.79 (+0.05), MRK: 58.96 (+0.44), CALA: 7.40 (-0.10), AVEO: 1.41 (+0.03), AGIO: 110.18 (+1.27), NVS: 103.75 (+0.57), ARRY: 5.81 (+0.06), CELGZ: 2.04 (+0.01), KPTI: 20.52 (+0.44)
Calithera Reports Phase I Data for CB-839 in Patients with Solid Tumors at the 2015 American Society of Clinical Oncology
GlobeNewswire - Sat May 30, 7:00AM CDT
-- Data Support Initiation of Multiple Solid Tumor Expansion Cohorts
CALA: 7.40 (-0.10)
Calithera Biosciences (CALA) in Focus, Stock Rises 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 22, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) shares rose almost 11% in the last trading session.
VRX: 257.53 (+3.25), CALA: 7.40 (-0.10)
Calithera Bio up 18% premarket on initial CB-839 study results
Seeking Alpha - at Seeking Alpha - Thu May 21, 8:08AM CDT
CALA: 7.40 (-0.10)
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 4.04 (+0.07), AMBX: (), CLDX: 23.55 (+0.03), AMGN: 176.59 (+4.90), LLY: 84.51 (-0.03), AMPE: 2.68 (+0.08), GSK: 43.44 (-0.15), BMY: 65.64 (+1.18), CLBS: 1.65 (-0.08), ARGS: 6.10 (-0.08), NK: 30.60 (-0.90), CALA: 7.40 (-0.10), EXEL: 5.73 (+0.19), XLRN: 28.64 (+0.54)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 26.22 (+0.43), ARQL: 1.71 (+0.08), LLY: 84.51 (-0.03), GSK: 43.44 (-0.15), EGRX: 96.62 (-0.16), BMY: 65.64 (+1.18), MRK: 58.96 (+0.44), AVEO: 1.41 (+0.03), CALA: 7.40 (-0.10), JUNO: 48.92 (+1.15), FPRX: 23.52 (+0.44), CXRX: 79.40 (-0.05)
5 Health Care Stocks Ready for Breakouts
at The Street - Fri Jul 17, 8:40AM CDT
These stocks look ready to break out and trade higher from current levels.
GNMK: 8.50 (+0.02), HWAY: 12.66 (+0.18), CALA: 7.40 (-0.10), AKBA: 9.40 (unch), OTIC: 25.77 (+0.26)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Thu Jul 16, 1:01PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PTX: 4.98 (+0.17), CALA: 7.40 (-0.10), MNKD: 4.29 (-0.17), SYMX: 1.25 (+0.02)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT
FIT: 47.60 (+2.41), PIRS: 3.20 (+0.14), KITE: 72.77 (+1.47), SRPT: 31.92 (+0.16), WSH: 46.49 (-0.13), CALA: 7.40 (-0.10), CLLS: 35.74 (+1.27), LBIO: 8.56 (+0.40), JUNO: 48.92 (+1.15), PNR: 60.81 (+0.07), APOL: 12.81 (-0.48), DSKX: 3.50 (+0.12)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jun 29, 4:35PM CDT
UAE: 20.45 (+0.02), TVIX: 5.70 (-0.02), BLCM: 20.35 (+0.35), EBIO: 2.77 (+0.02), XNET: 9.25 (+0.09), CALA: 7.40 (-0.10), BBEP: 3.03 (-0.26), AKBA: 9.40 (unch), LBIO: 8.56 (+0.40)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jun 19, 11:46AM CDT
FBIO: 3.37 (-0.09), ADXS: 16.66 (+0.84), ANY: 4.95 (-0.08), BITI: 17.93 (+0.16), JMEI: 18.71 (+1.42), ZAZA: 0.58 (-0.02), NSLP: 1.43 (-0.01), CORI: 14.66 (+0.66), TOPS: 1.17 (-0.03), UEC: 1.34 (-0.01), IPCI: 3.37 (-0.08), PLM: 0.94 (+0.01), CALA: 7.40 (-0.10), SPP: 1.65 (-0.03), ENRJ: 1.21 (unch), CARV: 6.05 (+0.17), PGN: 0.74 (-0.13), NNBR: 22.83 (-0.44), TCON: 13.62 (+0.45), WLDN: 10.32 (-0.02)
Calithera Biosciences to Present at the JMP Securities Life Sciences Conference 2015
GlobeNewswire - Tue Jun 16, 8:00AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the JMP Securities Life Sciences Conference 2015. Susan M. Molineaux, Ph.D., Founder, President and Chief Executive, will present on Tuesday, June 23, 2015 at 9:30 a.m. Eastern Time at The St. Regis Hotel in New York, NY. The presentation will be webcast live and available for replay for up to 30 days at www.calithera.com under the tab Investors.
CALA: 7.40 (-0.10)
Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Acute Leukemias at the 20th Congress of the European Hematology Association
GlobeNewswire - Thu Jun 11, 3:05PM CDT
Promising Clinical Activity With Early Signs of Biologic Activity, Tolerability, and Durability
CALA: 7.40 (-0.10)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 104.28 (+1.32), IDRA: 3.58 (+0.13), GILD: 117.86 (-0.04), CALA: 7.40 (-0.10), ABBV: 70.01 (-0.15), NVS: 103.75 (+0.57), CELGZ: 2.04 (+0.01), KPTI: 20.52 (+0.44)
ASCO Event Analyzer - 2015's Winners And Losers
EP Vantage - Seeking Alpha - Thu Jun 04, 1:42PM CDT
Neither Bristol-Myers Squibb (NYSE: BMY ) nor Puma Biotechnology (NYSE: PBYI ) can be scored numerically as the biggest loser coming out of ASCO, but in terms of sentiment, they were neck-and-neck for that title. Both took heavy losses after...
RXDX: 13.86 (+0.40), CLLS: 35.74 (+1.27), CALA: 7.40 (-0.10), IMGN: 18.02 (+0.12), JUNO: 48.92 (+1.15), CTIC: 1.85 (unch), BMY: 65.64 (+1.18), ONTY: 3.64 (+0.14), PBYI: 90.60 (+6.47)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qwcpw/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Conkwest, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG For more information visit http://www.researchandmarkets.com/research/7q...psed_acute
EPZM: 22.31 (-0.02), CTIC: 1.85 (unch), ABBV: 70.01 (-0.15), EXEL: 5.73 (+0.19), MGNX: 37.60 (+0.44), INCY: 104.28 (+1.32), AMGN: 176.59 (+4.90), BMY: 65.64 (+1.18), GSK: 43.44 (-0.15), ATNM: 2.26 (+0.10), AZN: 33.79 (+0.05), MRK: 58.96 (+0.44), CALA: 7.40 (-0.10), AVEO: 1.41 (+0.03), AGIO: 110.18 (+1.27), NVS: 103.75 (+0.57), ARRY: 5.81 (+0.06), CELGZ: 2.04 (+0.01), KPTI: 20.52 (+0.44)
Calithera Reports Phase I Data for CB-839 in Patients with Solid Tumors at the 2015 American Society of Clinical Oncology
GlobeNewswire - Sat May 30, 7:00AM CDT
-- Data Support Initiation of Multiple Solid Tumor Expansion Cohorts
CALA: 7.40 (-0.10)
Calithera Biosciences (CALA) in Focus, Stock Rises 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 22, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) shares rose almost 11% in the last trading session.
VRX: 257.53 (+3.25), CALA: 7.40 (-0.10)
Calithera Bio up 18% premarket on initial CB-839 study results
Seeking Alpha - at Seeking Alpha - Thu May 21, 8:08AM CDT
CALA: 7.40 (-0.10)
(0)
(0)